Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05077904




Registration number
NCT05077904
Ethics application status
Date submitted
30/09/2021
Date registered
14/10/2021
Date last updated
12/04/2024

Titles & IDs
Public title
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Scientific title
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Secondary ID [1] 0 0
2021-002686-18
Secondary ID [2] 0 0
EP0162
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Stereotypical Prolonged Seizures 0 0
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Staccato alprazolam
Other interventions - Placebo

Experimental: Staccato alprazolam Arm - Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.

Placebo Comparator: Placebo Arm - Participants randomized to this arm will receive a single dose of placebo by inhalation.


Treatment: Drugs: Staccato alprazolam
Route of administration: Inhalation
Participants will receive one dose of Staccato alprazolam during the Treatment Period.

Other interventions: Placebo
Route of administration: Inhalation
Participants will receive one dose of placebo during the Treatment Period.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration
Timepoint [1] 0 0
From start of IMP treatment through 6 hours
Primary outcome [2] 0 0
Treatment success for the treated seizure with no recurrence up to 2 hours
Timepoint [2] 0 0
From start of IMP treatment through 2 hours
Secondary outcome [1] 0 0
Treatment success for treated seizure with no recurrence after 4 hours
Timepoint [1] 0 0
From start of IMP treatment through 4 hours
Secondary outcome [2] 0 0
Treatment success for treated seizure with no recurrence after 6 hours
Timepoint [2] 0 0
From start of IMP treatment through 6 hours
Secondary outcome [3] 0 0
Time from IMP administration to cessation of the treated seizure
Timepoint [3] 0 0
From start of IMP treatment through 6 hours
Secondary outcome [4] 0 0
Frequency of respiratory treatment emergent adverse events (TEAEs)
Timepoint [4] 0 0
From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
Secondary outcome [5] 0 0
Number of subsequent seizure(s) up to 2 hours after IMP administration
Timepoint [5] 0 0
From start of IMP treatment through 2 hours
Secondary outcome [6] 0 0
Time to first subsequent seizure up to 2 hours after IMP administration
Timepoint [6] 0 0
From start of IMP treatment through 2 hours

Eligibility
Key inclusion criteria
- Participant must be =12 years of age at the Baseline/Randomization Visit

- Participant must have a study caregiver =18 years of age at the Screening Visit; the
study caregiver(s) must be a relative, partner, friend, or legally authorized
representative (LAR) of the participant, or a person who provides daily care to the
participant and has a significant personal relationship with the participant; the
study caregiver(s) must be able to recognize and observe the participant's seizures

- Participants with an established diagnosis of focal or generalized epilepsy or
combined focal and generalized epilepsy with a documented history of stereotypical
episodes of prolonged seizures that includes at least 1 of the following:

1. Generalized seizure episodes starting with a flurry of absence seizures or
myoclonic seizures with a minimum total duration of 5 minutes

2. Episodes of a focal seizure with a minimum duration of 3 minutes

3. Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90
seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum
total duration of 3 minutes

- Prior to the Screening Visit, participant has experienced =4 stereotypical episodes of
prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of
prolonged seizures must have occurred within the 3 months prior to the Screening Visit

- Participant has had a documented brain computerized tomography or magnetic resonance
imaging review, performed after diagnosis of epilepsy and within the 5 years prior to
the Screening Visit, that confirms the absence of a progressive neurological disorder

- Participant is receiving a regimen of antiseizure medications (ASMs) that has been
stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to
ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to
the Screening Visit

- Male and female participants:

1. A male participant must agree to use contraception during the Outpatient
Treatment Period and for at least 7 days after IMP administration and refrain
from donating sperm during this period

2. A female participant is eligible to participate if she is not pregnant, not
breastfeeding, and at least 1 of the following conditions applies:

i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow
the contraceptive guidance during the Outpatient Treatment Period and for at least 30
days after IMP administration

- Participant is capable of giving signed informed consent (or giving assent, where
required), which includes compliance with the requirements and restrictions listed in
the informed consent form (ICF), the protocol, and the individualized participant
management plan (iPMP). The ICF or a specific assent form, where required, will be
signed and dated by minors

- The participant's study caregiver(s) must be capable of giving signed informed
consent, which includes compliance with the requirements and restrictions listed in
the ICF, the protocol, and the iPMP
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participant has a current history of alcohol or drug use disorder, as defined in the
Diagnostic and Statistical Manual of Mental Disorders 5, within the previous 1 year

- Participant has a known hypersensitivity to any components of the IMP or comparable
drugs (and/or an investigational device) as stated in this protocol or to albuterol
(or similar bronchospasm rescue medication if needed to meet country-specific
requirements)

- Participant has a diagnosis of atrial fibrillation or mitral stenosis

- Participant has a history of convulsive (generalized tonic-clonic) status epilepticus
in the 8 weeks prior to the Screening Visit

- Participant has a history or presence of known nonepileptic seizures which cannot be
distinguished from qualifying epileptic seizures

- Participant has a clinically significant known airway hypersensitivity (eg,
bronchospasm to known allergens, such as pollen, animals, or food) and/or acute
respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)

- Participant has a clinically significant chronic pulmonary disorder other than mild
asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases
[including idiopathic pulmonary fibrosis]) and/or recent history or presence of
hemoptysis or pneumothorax

- Participant has had a positive antigen test for acute respiratory syndrome coronavirus
2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory
distress necessitating hospitalization or outpatient treatment such as ambulatory
oxygen, extensive treatment with inhaler medications, and/or oral medications for a
duration of 4 weeks or more, unless full resolution occurred at least 6 months prior
to Screening

- Participant has experienced a upper respiratory tract infection within 4 weeks or
bronchitis/pneumonia within 3 months before the Screening Visit

- Participant has a history or presence of acute narrow-angle glaucoma

- Participant has a condition for which oral alprazolam is contraindicated (eg,
myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)

- Participant has a history or presence of long QT syndrome, a family history of sudden
death due to long QT syndrome, or unexplained syncope

- Chronic use of benzodiazepines for more than 3 days within a period of 7 days will be
allowed for approximately 30 % of study participants

- Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole
antifungal agents (ketoconazole and itraconazole) and nefazodone

- Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative
hypnotics on a chronic basis

- Participant is taking nonselective beta blockers on a chronic basis

- Participant is taking pharmacotherapy for an active major psychiatric disorder where
major changes in regimen are needed or anticipated during the study

- Participant has been treated with vagal nerve stimulation (VNS) for less than 6 months
or VNS settings have changed within 30 days before the Screening Visit

- Participant has a clinically significant laboratory abnormality that may increase the
risk associated with study participation or may interfere with the interpretation of
study results, according to the judgment of the Investigator

- Participant has an oxygen saturation <95 % (or less than normal in regions of altitude
>2500 meters) for greater than 30 seconds during the Screening Visit. In case of an
out-of-range result, 1 repeat will be allowed. If the readings are out of range again,
the study participant will be excluded

- Participant has >2.0x upper limit of normal (ULN) of any of the following: alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP),
or >1.0xULN total bilirubin (=1.5xULN total bilirubin if known Gilbert's syndrome or
>2.0xULN total bilirubin for liver impairment)

- Participant has current unstable liver or biliary disease per Investigator assessment
defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia,
esophageal or gastric varices, persistent jaundice, or cirrhosis

- Participant has a QT interval corrected for heart rate (QTc) >450 msec (males), QTc
interval >470 msec (females), or QTc interval >480 msec (participants with bundle
branch block), PR interval =220 msec, or any other clinically significant
electrocardiogram (ECG) abnormality according to the Investigator i) The QTc is the QT
interval corrected for heart rate according to Fridericia's formula (QTcF). It is
either machine-read or manually over-read

- Participant has a positive urine screen for drugs of abuse at the Screening Visit

- Participant has a blood pressure (BP) or heart rate (HR) outside the following range
after 5 minutes rest: systolic BP: 90 mmHg to 150 mmHg; diastolic BP: 4 0mmHg to 95
mmHg; HR: 50 bpm to 100 bpm. In case of an out-of-range result, 1 repeat will be
allowed. If the readings are out of range again, the study participant will be
excluded

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
17/04/2024
Actual
Sample size
Target
250
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Ep0162 30016 - Fitzroy
Recruitment hospital [2] 0 0
Ep0162 30030 - Herston
Recruitment hospital [3] 0 0
Ep0162 30027 - Melbourne
Recruitment hospital [4] 0 0
Ep0162 30031 - South Brisbane
Recruitment postcode(s) [1] 0 0
- Fitzroy
Recruitment postcode(s) [2] 0 0
- Herston
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nevada
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Blagoevgrad
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Pazardzhik
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Pleven
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Sofia
Country [31] 0 0
China
State/province [31] 0 0
Beijing
Country [32] 0 0
China
State/province [32] 0 0
Changchun
Country [33] 0 0
China
State/province [33] 0 0
Chengdu
Country [34] 0 0
China
State/province [34] 0 0
Chongqing
Country [35] 0 0
China
State/province [35] 0 0
Guangzhou
Country [36] 0 0
China
State/province [36] 0 0
Lanzhou
Country [37] 0 0
China
State/province [37] 0 0
Nanchang
Country [38] 0 0
China
State/province [38] 0 0
Nanjing
Country [39] 0 0
China
State/province [39] 0 0
Shanghai
Country [40] 0 0
China
State/province [40] 0 0
Shijiazhuang
Country [41] 0 0
China
State/province [41] 0 0
Suzhou
Country [42] 0 0
China
State/province [42] 0 0
Tianjin
Country [43] 0 0
China
State/province [43] 0 0
Wenzhou
Country [44] 0 0
China
State/province [44] 0 0
Wuhan
Country [45] 0 0
China
State/province [45] 0 0
Yinchuan
Country [46] 0 0
China
State/province [46] 0 0
Zhanjiang
Country [47] 0 0
China
State/province [47] 0 0
Zhengzhou
Country [48] 0 0
Czechia
State/province [48] 0 0
Brno
Country [49] 0 0
Czechia
State/province [49] 0 0
Ostrava - Poruba
Country [50] 0 0
Czechia
State/province [50] 0 0
Praha 4
Country [51] 0 0
Czechia
State/province [51] 0 0
Praha 5
Country [52] 0 0
Czechia
State/province [52] 0 0
Praha 6
Country [53] 0 0
France
State/province [53] 0 0
Bron
Country [54] 0 0
France
State/province [54] 0 0
Dijon
Country [55] 0 0
France
State/province [55] 0 0
Marseille Cedex 5
Country [56] 0 0
France
State/province [56] 0 0
Paris
Country [57] 0 0
France
State/province [57] 0 0
Rennes
Country [58] 0 0
France
State/province [58] 0 0
Strasbourg Cedex
Country [59] 0 0
Germany
State/province [59] 0 0
Aachen
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Bielefeld
Country [62] 0 0
Germany
State/province [62] 0 0
Erlangen
Country [63] 0 0
Germany
State/province [63] 0 0
Frankfurt Am Main
Country [64] 0 0
Germany
State/province [64] 0 0
Kehl-kork
Country [65] 0 0
Germany
State/province [65] 0 0
Marburg
Country [66] 0 0
Germany
State/province [66] 0 0
München
Country [67] 0 0
Hungary
State/province [67] 0 0
Balassagyarmat
Country [68] 0 0
Hungary
State/province [68] 0 0
Budapest
Country [69] 0 0
Hungary
State/province [69] 0 0
Debrecen
Country [70] 0 0
Italy
State/province [70] 0 0
Catanzaro
Country [71] 0 0
Italy
State/province [71] 0 0
Genova
Country [72] 0 0
Italy
State/province [72] 0 0
Milano
Country [73] 0 0
Italy
State/province [73] 0 0
Pavia
Country [74] 0 0
Italy
State/province [74] 0 0
Roma
Country [75] 0 0
Japan
State/province [75] 0 0
Fukuoka
Country [76] 0 0
Japan
State/province [76] 0 0
Hamamatsu
Country [77] 0 0
Japan
State/province [77] 0 0
Hiroshima-shi
Country [78] 0 0
Japan
State/province [78] 0 0
Hofu
Country [79] 0 0
Japan
State/province [79] 0 0
Itami
Country [80] 0 0
Japan
State/province [80] 0 0
Kodaira
Country [81] 0 0
Japan
State/province [81] 0 0
Koshi
Country [82] 0 0
Japan
State/province [82] 0 0
Nagakute
Country [83] 0 0
Japan
State/province [83] 0 0
Nagoya
Country [84] 0 0
Japan
State/province [84] 0 0
Niigata
Country [85] 0 0
Japan
State/province [85] 0 0
Omura
Country [86] 0 0
Japan
State/province [86] 0 0
Osaka
Country [87] 0 0
Japan
State/province [87] 0 0
Sapporo
Country [88] 0 0
Japan
State/province [88] 0 0
Shinjuku-ku
Country [89] 0 0
Japan
State/province [89] 0 0
Shizuoka
Country [90] 0 0
Japan
State/province [90] 0 0
Suita
Country [91] 0 0
Japan
State/province [91] 0 0
Toon
Country [92] 0 0
Japan
State/province [92] 0 0
Yamagata
Country [93] 0 0
Poland
State/province [93] 0 0
Bydgoszcz
Country [94] 0 0
Poland
State/province [94] 0 0
Gdansk
Country [95] 0 0
Poland
State/province [95] 0 0
Krakow
Country [96] 0 0
Poland
State/province [96] 0 0
Lublin
Country [97] 0 0
Poland
State/province [97] 0 0
Nowa Sol
Country [98] 0 0
Poland
State/province [98] 0 0
Poznan
Country [99] 0 0
Poland
State/province [99] 0 0
Swidnik
Country [100] 0 0
Spain
State/province [100] 0 0
Barcelona
Country [101] 0 0
Spain
State/province [101] 0 0
Hospitalet de Llobregat
Country [102] 0 0
Spain
State/province [102] 0 0
Madrid
Country [103] 0 0
Spain
State/province [103] 0 0
Pamplona
Country [104] 0 0
Spain
State/province [104] 0 0
Sevilla
Country [105] 0 0
Spain
State/province [105] 0 0
Terrassa
Country [106] 0 0
Spain
State/province [106] 0 0
Valencia
Country [107] 0 0
Spain
State/province [107] 0 0
Valladolid
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Birmingham
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Cardiff
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Oxford
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
UCB Biopharma SRL
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to assess the success of a single administration of Staccato
alprazolam compared with placebo both in rapidly terminating a seizure episode within 90
seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal
product (IMP) administration.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05077904
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
UCB Cares
Address 0 0
001 844 599 2273 (UCB)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
UCB Cares
Address 0 0
Country 0 0
Phone 0 0
1-844-599-2273 (USA)
Fax 0 0
Email 0 0
UCBCares@ucb.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05077904